C(3)N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease

Despite the accumulating evidence linking the development of Alzheimer’s disease (AD) to the aggregation of Aβ peptides and the emergence of Aβ oligomers, the FDA has approved very few anti-aggregation-based therapies over the past several decades. Here, we report the discovery of an Aβ peptide aggr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xiuhua, Zhou, Hong, Zhang, Mengling, Su, Juan, Wang, Xiao, Li, Sijie, Yang, Zaixing, Kang, Zhenhui, Zhou, Ruhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504243/
https://www.ncbi.nlm.nih.gov/pubmed/37714837
http://dx.doi.org/10.1038/s41467-023-41489-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504243/
https://www.ncbi.nlm.nih.gov/pubmed/37714837
http://dx.doi.org/10.1038/s41467-023-41489-y

Ejemplares similares